Synthetic Oligosaccharide-Based Vaccines Protect Mice from Clostridioides difficile Infections

Broecker F, Wegner E, Seco BM, Kaplonek P, Bräutigam M, Enßer A, Pfister F, Daniel C, Martin CE, Mattner J, Seeberger PH (2019)

Publication Type: Journal article

Publication year: 2019

Journal

DOI: 10.1021/acschembio.9b00642

Abstract

Infections with Clostridioides difficile (formerly Clostridium difficile) have increased in incidence, morbidity, and mortality over the past decade. Preventing infections is becoming increasingly important, as frontline antibiotics become less effective and frequently induce recurrence by disrupting intestinal microbiota. The clinically most advanced vaccine approaches prevent symptoms once C. difficile infection is established by inducing immunity to secreted clostridial cytotoxins. However, they do not inhibit bacterial colonization and thereby favor asymptomatic carriage. Synthetic oligosaccharides resembling the C. difficile surface glycans PS-I, PS-II, and PS-III are immunogenic and serve as basis for colonization-preventing vaccines. Here, we demonstrate that glycoconjugate vaccine candidates based on synthetic oligosaccharides protected mice from infections with two different C. difficile strains. Four synthetic antigens, ranging in size from disaccharides to hexasaccharides, were conjugated to CRM197, which is a carrier protein used in commercial vaccines. The vaccine candidates induced glycan-specific antibodies in mice and substantially limited C. difficile colonization and colitis after experimental infection. The glycoconjugates ameliorated intestinal pathology more substantially than a toxin-targeting vaccine. Colonization of the gut by C. difficile was selectively inhibited while intestinal microbiota remained preserved. Passive transfer experiments with anti-PS-I serum revealed that protection is mediated by specific antiglycan antibodies; however, cell-mediated immunity likely also contributed to protection in vivo. Thus, glycoconjugate vaccines against C. difficile are a complementary approach to toxin-targeting strategies and are advancing through preclinical work.

Authors with CRIS profile

Involved external institutions

Max-Planck-Institut für Kolloid- und Grenzflächenforschung / Max Planck Institute of Colloids and Interfaces Germany (DE)

How to cite

APA:

Broecker, F., Wegner, E., Seco, B.M., Kaplonek, P., Bräutigam, M., Enßer, A.,... Seeberger, P.H. (2019). Synthetic Oligosaccharide-Based Vaccines Protect Mice from Clostridioides difficile Infections. ACS Chemical Biology. https://doi.org/10.1021/acschembio.9b00642

MLA:

Broecker, Felix, et al. "Synthetic Oligosaccharide-Based Vaccines Protect Mice from Clostridioides difficile Infections." ACS Chemical Biology (2019).

BibTeX: Download